ArticleDiabetology & metabolic syndrome2013
Anti-diabetic treatment regulates pro-fibrotic TGF-β serum levels in type 2 diabetics.
Article in Diabetology & metabolic syndrome, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Investigation of the protective effects of dichloroacetic acid in a rat model of diabetic neuropathy.BMC pharmacology & toxicology · 2025Article
- Reciprocal Regulation of Hepatic TGF-β1 and Foxo1 Controls Gluconeogenesis and Energy Expenditure.Diabetes · 2023Article
- Altered Secretome of Diabetic Monocytes Could Negatively Influence Fracture Healing-An In Vitro Study.International journal of molecular sciences · 2021Article
- Use of in vitro bone models to screen for altered bone metabolism, osteopathies, and fracture healing: challenges of complex models.Archives of toxicology · 2020Review
- Histomorphological, VEGF and TGF-β immunoexpression changes in the diabetic rats' ovary and the potential amelioration following treatment with metformin and insulin.Journal of molecular histology · 2020Article
- Ileal interposition surgery targets the hepatic TGF-β pathway, influencing gluconeogenesis and mitochondrial bioenergetics in the UCD-T2DM rat model of diabetes.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives.Oncology letters · 2017Article
- TGF-βJournal of molecular medicine (Berlin, Germany) · 2017Article
- Isolation and cytokine analysis of lamina propria lymphocytes from mucosal biopsies of the human colon.Journal of immunological methods · 2015Article
- TGF-β signaling regulates fibrotic expression and activity in carpal tunnel syndrome.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2014Article
- Gene expression changes in cancellous bone of type 2 diabetics: a biomolecular basis for diabetic bone disease.Langenbeck's archives of surgery · 2014Article
- Targets and candidate agents for type 2 diabetes treatment with computational bioinformatics approach.Journal of diabetes research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe single-center, open-label, four-arm, exploratory study investigates the relation of different anti-diabetics to serum levels of active TGF-β, a known pro-fibrotic stimulus, before and after a defined test meal.
findingsWe investigated sera of patients with type 2 diabetes mellitus (T2DM) treated with metformin and sulfonylurea, insulin glargine or a DPP-4 inhibitor (DPP4i). Patients' sera were analyzed before and 5 h after a defined test meal at intervals of 30 min.The sulfonylurea/metformin group exhibited the highest basal levels of active TGF-β (31.50 ± 3.58 ng/ml). The glargine/metformin group had active TGF-β levels (24.98 ± 1.90 ng/ml) that were comparable to those of the healthy participants (22.12 ± 2.34 ng/ml). The lowest basal levels of active TGF-β were detected in the DPP-4i/metformin group (12.28 ± 0.84 ng/ml). Following the intake of a standardized meal, active TGF-β levels decreased (approx. 30%) in healthy subjects as well as in the sulfonylurea/metformin group and in the glargine/metformin group. After 5 h, the active TGF-β levels were normalized to basal levels. Active TGF-β levels in the DPP-4i/metformin group did not change significantly after the test meal. Overall plasma levels of insulin and proinsulin were comparable between healthy participants, and T2DM patients in the glargin/metformin group and in the DPP4i/metformin group. However, no correlation between active TGF-β levels, glucose, insulin or pro-insulin levels was detected.
conclusionsT2DM patients often exhibit elevated levels of pro-fibrotic active TGF-β. Our results suggest that glargine/metformin and DPP4i/metformin treatment may more effectively reduce active TGF-β serum levels than the sulfonylurea/metformin treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.